Biohaven LTD 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE

3 Mar 2025

BHVN

10-K: Biohaven Ltd. Reports Full Year 2024 Results, Highlights Clinical Pipeline Advancements

Biohaven Ltd.'s 2024 10-K filing outlines the company's financial performance, clinical trial progress, and strategic initiatives across its immunology, neuroscience, and oncology programs.

NYSE

29 Feb 2024

BHVN

Biohaven LTD

10-K: Biohaven Pharmaceuticals Reports Progress Across Multiple Drug Development Platforms in 2023

Biohaven Pharmaceuticals outlines advancements in its diverse clinical and preclinical programs, including updates on ongoing trials and regulatory interactions.